In patients with high stage tumor (≧pT3, n = 54), the patients with high STAT3 tumor had a significantly higher risk of both disease progression (p = 0.035) and cancer-specific mortality (p = 0.012), but not with tumors expressing high S1PR1 (p = 0.193 and p = 0.159, respectively) or high IL-6 (p = 0.609 and p = 0.365, respectively). Here, S1PR1 is linked to cancer.